Safety and Efficacy Study of SHAPE Gel in Alopecia Areata

Inclusion Criteria: * Diagnosis of scalp alopecia areata and scalp hair loss due to alopecia areata for a minimum of six months and a maximum of two years. * Patients taking thyroid medication or hormonal therapy must be on a stable dose for 6 months and maintain such throughout the study. * Willingness to maintain same hair style, including shampoo and hair dye, throughout the study period. * Willingness to have a small micro dot tattoo placed to allow for photographic analysis of treatment and application of study medication. Exclusion Criteria: * History of systemic or cutaneous malignancy and/or lymphoproliferative disease, other than patients with: up to 3 basal cell carcinoma; up to three well differentiated cutaneous squamous cell carcinoma; and/or cervical intraepithelial neoplasm (CIN), treated successfully with no evidence of disease, and treated for greater than 6 months prior to study entry. * Current actinic keratosis on the scalp and/or face * Nevi or cutaneous lesions thought suspicious for malignancy. * History of or current gastrointestinal, pulmonary, cardiovascular, genitourinary or hematological disease, CNS disorders, infectious disease or coagulation disorders that would preclude participation in and completion of study assessments. * Positive for hepatitis B surface antigen, HIV or hepatitis C. * Co-existent androgenetic alopecia: in males: Norwood-Hamilton stage IV, V or VI; in females: Ludwig stage II or III. * Unwillingness to discontinue use of non-breathable wigs, weaves or shaving of scalp throughout course of study.